Pharmacological Treatment of Anxiety Disorders

Anxiety disorders are among the most common mental health conditions worldwide, characterised by excessive fear and worry that impairs daily functioning. Pharmacological interventions aim to correct dysregulated neurotransmitter systems within neural circuits mediating threat detection and stress responses. First-line treatments comprise selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors, which target serotonergic and noradrenergic transmission to reduce anxiety symptoms over weeks of administration. For rapid symptom relief, benzodiazepines acting on gamma-aminobutyric acid type A receptors are employed, though their use is tempered by sedation, tolerance and dependency risks. Adjunctive options include azapirones, antihistamines, beta-adrenoceptor antagonists and certain anticonvulsants, each offering distinct advantages for specific symptom clusters or comorbidities. Clinical guidelines typically recommend a minimum of six to twelve months of continued pharmacotherapy following remission to prevent relapse. Despite the efficacy of established agents, a substantial proportion of patients display partial response or intolerance, prompting research into novel mechanisms. Emerging strategies focus on modulation of glutamatergic signalling, neuropeptides, neurosteroids, endocannabinoid and cholinergic systems, as well as precision-medicine approaches integrating genetic, neuroimaging and behavioural biomarkers to optimise individualised regimens.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Treatment of Anxiety Disorders publication trend

The graph below shows the total number of articles in pharmacological treatment of anxiety disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Selective serotonin reuptake inhibitors (SSRIs): Drugs that block serotonin reabsorption into presynaptic neurons, enhancing serotonergic transmission.

Serotonin-noradrenaline reuptake inhibitors (SNRIs): Agents that inhibit the reuptake of both serotonin and noradrenaline, modulating mood and anxiety.

GABAergic agents: Compounds acting on gamma-aminobutyric acid receptors to potentiate the brain’s primary inhibitory neurotransmission.

Glutamate modulators: Drugs that alter excitatory neurotransmission mediated by glutamate receptors, with potential rapid anxiolytic effects.

Allosteric modulator: A substance that binds to a receptor at a site distinct from the active (“orthosteric”) site, modifying receptor response to the natural ligand.

References

1. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in Psychiatry (2020).
2. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacology & Therapeutics (2019).
3. Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology. Frontiers in Psychiatry (2020).
4. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis. PLOS Medicine (2021).
5. Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalized Anxiety Disorder. Biological Psychiatry (2020).